Efficacy, Safety and Tolerability of CG428 Cutaneous Solution on Chemotherapy Induced Alopecia; Controlled Study (ELAN)

Inclusion Criteria:

* Adult female, age ≥ 18 years.
* Patient with cancer, requiring one of the following pre-specified chemotherapy regimen according to local guidelines: weekly paclitaxel, weekly docetaxel, eribuline or associationof weekly paclitaxel/docetaxel with carboplatine (association of targeted therapies not influencing significantly the risk of alopecia is allowed, i.e. trastuzumab, pertuzumab or bevacizumab).
* Healthy hair (no current alopecia or scalp disease treatment).
* Life expectancy ≥ 6 months.
* Able to use the study treatment in compliance with the protocol.
* Physical and psychological ability to participate.
* Negative serum pregnancy test within 14 days prior to randomization in premenopausal women with childbearing potential.
* Patients must agree to not shave their head (minimum ≥ 1 cm).
* Signed and dated informed consent.

Exclusion Criteria:

* Other ongoing anti-neoplastic therapy or other investigational drug with potential effect on hair growth.
* Patients treated with proteasome inhibitors, i.e. bortezomib.
* Prior radiotherapy to the scalp with residual alopecia.
* Known allergy or hypersensitivity to some components of CG 428 cutaneous solution (including allium cepa (onion), citrus, caffeine, theobromine).
* Pre-existing alopecia or significant scalp disease, which may alter study treatment administration or absorption.
* Concomitant use of cold cap or any other anti-hair loss treatment.
* Hair transplants.